01 - Evaluating Poly-Pharmacy and Drug Interactions in Cardiovascular Treatment: A Ca...
http://dx.doi.org/10.31703/gpsr.2024(IX-II).0110.31703/gpsr.2024(IX-II).01 Published : Jun 2024
-
Drug-drug interactions (DDIs) have a considerable impact on therapeutic response which, in turn, could result in adverse drug reactions (ADRs), or even treatment failure. It was directed at patients with cardiovascular diseases (CVDs) as this patient group is more likely to experience DDIs owing to the complexity and number of their drug treatments. The study, analyzed 108 prescriptions using diff... Details
-
Cardiovascular Diseases, Drug-drug Interactions (DDIââ¬â¢s), Poly-pharmacy
-
(1) Muhammad Adnan
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
(2) Savera Saghir
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
(3) Ejaz Ahmed
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
(4) Aimen Sahar
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
(5) Ahmad Jalal Masood
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
02 - Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approach...
http://dx.doi.org/10.31703/gpsr.2024(IX-II).0210.31703/gpsr.2024(IX-II).02 Published : Jun 2024
-
Immunotherapy is a medical intervention in which certain immune system components are used to combat disease. Usually, immunotherapy works by helping the body fight off the offending substance by modifying it as well as boosting the immune system. Biologic therapy or biotherapy are additional terms for certain forms of immunotherapy. Different advances and novel approaches have been studied such a... Details
-
Cancer, ADCs, Immunotherapeutic, Oral Immunotherapeutic, Combination Therapies, Targeted Therapies, Adverse Effects, Challenges, Advancement in Immunotherapy
-
(1) Kalya Ahmad Sandhu
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
(2) Asawar Yameen
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
(3) Naima Zafar
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
(4) Hira Ali
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
(5) Usama Abid
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
(6) Mishkaat Raza
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
03 - Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next G...
http://dx.doi.org/10.31703/gpsr.2024(IX-II).0310.31703/gpsr.2024(IX-II).03 Published : Jun 2024
-
This review focuses on the physicochemical properties of nanocarriers (NCs) and the physical properties of the tumor microenvironment (TME), highlighting strategies used to specifically deliver molecules of interest to specific lesions. This review discusses these products, explains the simple selection of high-performance and active methods, and illustrates this with examples of drugs that are fo... Details
-
NP (nanoparticles), EPR (Enhanced permeation and retention), TME (tumor microenvironment), MDR (multiple drug resistance), HCC (hepatic cell carcinoma), SDDS (Smart Drug Delivery Systems)
-
(1) Dua Zahid
Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.
(2) Rabia Tahir
Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.
(3) Wajiha Ashfaq
Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.
(4) Abdul Wasay
Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.
(5) Qamer Iqbal
Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.
04 - Analyzing Euglycemic Diabetic Ketoacidosis Trends Amidst the Rise of SGLT-2 Inhi...
http://dx.doi.org/10.31703/gpsr.2024(IX-II).0410.31703/gpsr.2024(IX-II).04 Published : Jun 2024
-
This overview investigates the increasing prevalence of sodium-glucose cotransporter-2 (SGLT-2) inhibitor-associated euglycemic diabetic ketoacidosis (EDKA) in type II diabetes patients. Due to its tendency to occur with normal or somewhat high blood sugar levels, EDKA poses unique obstacles to diagnosis and treatment. Based on an extensive review of recent literature, we examine clinical motifs, ... Details
-
DKA, Euglycemic Diabetic Ketoacidosis (EDKA), SGLT-2 Inhibitors, Type II Diabetes, Patient Education
-
(1) Muhammad Adnan
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
(2) Ejaz Ahmed
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
(3) Aimen Sahar
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
(4) Savera Saghir
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
(5) Mohammad Hossein Rafieikia
Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
(6) Ahtasham Saleem
Graduate, Bioscience Department, COMSATS University Islamabad, Pakistan.
Volume IX, Issue II (Spring 2024) 
Volume IX, Issue I (Winter 2024) 
Volume VIII, Issue IV (Fall 2023) 
Volume VIII, Issue III (Summer 2023) 
Volume VIII, Issue II (Spring 2023) 
Volume VIII, Issue I (Winter 2023) 
Volume VII, Issue I (Fall 2022) 
Volume VI, Issue II (Fall 2021) 
Volume VI, Issue I (Spring 2021) 
Volume V, Issue I (Fall 2020) 
Volume IV, Issue I (Fall 2019) 
Volume III, Issue I (Fall 2018) 
Volume II, Issue I (Fall 2017) 
Volume I, Issue I (Fall 2016)